NCT00251979

A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer

A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Undergone Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer - the PUB Study.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,312 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being carried out to see if constant 3 days infusion of Nexium is effective in preventing rebleeding after an endoscopic treatment.

Conditions

• Gastrointestinal Hemorrhage

Interventions

Type	Name	Description
DRUG	Esomeprazole

Timeline

• Start date: 2005-10-01
• Primary completion: 2007-12-01
• Completion: 2007-12-01
• First posted: 2005-11-11
• Last updated: 2011-06-17
• Results posted: 2011-06-17

Locations

78 sites across 16 countries: Austria, Denmark, Finland, France, Germany, Greece, Hong Kong, Netherlands, Norway, Romania, Russia, South Africa, Spain, Sweden, Turkey (Türkiye), United Kingdom